WETAMD

Clinical trials for WETAMD explained in plain language.

Never miss a new study

Get alerted when new WETAMD trials appear

Sign up with your email to follow new studies for WETAMD, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

One-Shot gene therapy could end frequent eye injections for wet AMD

Disease control Recruiting now

This study tests a one-time gene therapy called RGX-314 for wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if it can control the disease as well as standard treatments that require eye injections every few months. About 714 adults a…

Matched conditions: WETAMD

Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control

Last updated May 14, 2026 12:05 UTC

WETAMD

Get alerted when new WETAMD trials appear

One-Shot gene therapy could end frequent eye injections for wet AMD